Frontotemporal degeneration, the next therapeutic frontier

Molecules and animal models for frontotemporal degeneration drug development

Adam L. Boxer, Michael Gold, Edward Huey, Fen Biao Gao, Edward A. Burton, Tiffany Chow, Aimee Kao, Blair R. Leavitt, Bruce Lamb, Megan Grether, David S Knopman, Nigel J. Cairns, Ian R. Mackenzie, Laura Mitic, Erik D. Roberson, Daniel Van Kammen, Marc Cantillon, Kathleen Zahs, Stephen Salloway, John Morris & 9 others Gary Tong, Howard Feldman, Howard Fillit, Susan Dickinson, Zaven Khachaturian, Margaret Sutherland, Robert Farese, Bruce L. Miller, Jeffrey Cummings

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has identified a number of promising therapeutic targets as well as animal models in which to develop drugs. The close association of some forms of FTD with neuropathological accumulation of tau protein or increased neuroinflammation due to progranulin protein deficiency suggests that a drug's success in treating FTD may predict efficacy in more common diseases such as Alzheimer's disease. A variety of regulatory incentives, clinical features of FTD such as rapid disease progression, and relatively pure molecular pathology suggest that there are advantages to developing drugs for FTD as compared with other more common neurodegenerative diseases such as Alzheimer's disease. In March 2011, the Frontotemporal Degeneration Treatment Study Group sponsored a conference entitled "FTD, the Next Therapeutic Frontier," which focused on preclinical aspects of FTD drug development. The goal of the meeting was to promote collaborations between academic researchers and biotechnology and pharmaceutical researchers to accelerate the development of new treatments for FTD. Here we report the key findings from the conference, including the rationale for FTD drug development; epidemiological, genetic, and neuropathological features of FTD; FTD animal models and how best to use them; and examples of successful drug development collaborations in other neurodegenerative diseases.

Original languageEnglish (US)
Pages (from-to)176-188
Number of pages13
JournalAlzheimer's and Dementia
Volume9
Issue number2
DOIs
StatePublished - Mar 2013

Fingerprint

Animal Models
Pharmaceutical Preparations
Neurodegenerative Diseases
Therapeutics
Alzheimer Disease
Research Personnel
tau Proteins
Protein Deficiency
Molecular Pathology
Explosions
Biotechnology
Dementia
Disease Progression
Motivation

Keywords

  • Frontotemporal degeneration
  • Progranulin
  • Tau
  • TDP-43
  • Treatment

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Frontotemporal degeneration, the next therapeutic frontier : Molecules and animal models for frontotemporal degeneration drug development. / Boxer, Adam L.; Gold, Michael; Huey, Edward; Gao, Fen Biao; Burton, Edward A.; Chow, Tiffany; Kao, Aimee; Leavitt, Blair R.; Lamb, Bruce; Grether, Megan; Knopman, David S; Cairns, Nigel J.; Mackenzie, Ian R.; Mitic, Laura; Roberson, Erik D.; Van Kammen, Daniel; Cantillon, Marc; Zahs, Kathleen; Salloway, Stephen; Morris, John; Tong, Gary; Feldman, Howard; Fillit, Howard; Dickinson, Susan; Khachaturian, Zaven; Sutherland, Margaret; Farese, Robert; Miller, Bruce L.; Cummings, Jeffrey.

In: Alzheimer's and Dementia, Vol. 9, No. 2, 03.2013, p. 176-188.

Research output: Contribution to journalArticle

Boxer, AL, Gold, M, Huey, E, Gao, FB, Burton, EA, Chow, T, Kao, A, Leavitt, BR, Lamb, B, Grether, M, Knopman, DS, Cairns, NJ, Mackenzie, IR, Mitic, L, Roberson, ED, Van Kammen, D, Cantillon, M, Zahs, K, Salloway, S, Morris, J, Tong, G, Feldman, H, Fillit, H, Dickinson, S, Khachaturian, Z, Sutherland, M, Farese, R, Miller, BL & Cummings, J 2013, 'Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development', Alzheimer's and Dementia, vol. 9, no. 2, pp. 176-188. https://doi.org/10.1016/j.jalz.2012.03.002
Boxer, Adam L. ; Gold, Michael ; Huey, Edward ; Gao, Fen Biao ; Burton, Edward A. ; Chow, Tiffany ; Kao, Aimee ; Leavitt, Blair R. ; Lamb, Bruce ; Grether, Megan ; Knopman, David S ; Cairns, Nigel J. ; Mackenzie, Ian R. ; Mitic, Laura ; Roberson, Erik D. ; Van Kammen, Daniel ; Cantillon, Marc ; Zahs, Kathleen ; Salloway, Stephen ; Morris, John ; Tong, Gary ; Feldman, Howard ; Fillit, Howard ; Dickinson, Susan ; Khachaturian, Zaven ; Sutherland, Margaret ; Farese, Robert ; Miller, Bruce L. ; Cummings, Jeffrey. / Frontotemporal degeneration, the next therapeutic frontier : Molecules and animal models for frontotemporal degeneration drug development. In: Alzheimer's and Dementia. 2013 ; Vol. 9, No. 2. pp. 176-188.
@article{1eed3d9d00f84b04a3d3841e1e56daca,
title = "Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development",
abstract = "Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has identified a number of promising therapeutic targets as well as animal models in which to develop drugs. The close association of some forms of FTD with neuropathological accumulation of tau protein or increased neuroinflammation due to progranulin protein deficiency suggests that a drug's success in treating FTD may predict efficacy in more common diseases such as Alzheimer's disease. A variety of regulatory incentives, clinical features of FTD such as rapid disease progression, and relatively pure molecular pathology suggest that there are advantages to developing drugs for FTD as compared with other more common neurodegenerative diseases such as Alzheimer's disease. In March 2011, the Frontotemporal Degeneration Treatment Study Group sponsored a conference entitled {"}FTD, the Next Therapeutic Frontier,{"} which focused on preclinical aspects of FTD drug development. The goal of the meeting was to promote collaborations between academic researchers and biotechnology and pharmaceutical researchers to accelerate the development of new treatments for FTD. Here we report the key findings from the conference, including the rationale for FTD drug development; epidemiological, genetic, and neuropathological features of FTD; FTD animal models and how best to use them; and examples of successful drug development collaborations in other neurodegenerative diseases.",
keywords = "Frontotemporal degeneration, Progranulin, Tau, TDP-43, Treatment",
author = "Boxer, {Adam L.} and Michael Gold and Edward Huey and Gao, {Fen Biao} and Burton, {Edward A.} and Tiffany Chow and Aimee Kao and Leavitt, {Blair R.} and Bruce Lamb and Megan Grether and Knopman, {David S} and Cairns, {Nigel J.} and Mackenzie, {Ian R.} and Laura Mitic and Roberson, {Erik D.} and {Van Kammen}, Daniel and Marc Cantillon and Kathleen Zahs and Stephen Salloway and John Morris and Gary Tong and Howard Feldman and Howard Fillit and Susan Dickinson and Zaven Khachaturian and Margaret Sutherland and Robert Farese and Miller, {Bruce L.} and Jeffrey Cummings",
year = "2013",
month = "3",
doi = "10.1016/j.jalz.2012.03.002",
language = "English (US)",
volume = "9",
pages = "176--188",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Frontotemporal degeneration, the next therapeutic frontier

T2 - Molecules and animal models for frontotemporal degeneration drug development

AU - Boxer, Adam L.

AU - Gold, Michael

AU - Huey, Edward

AU - Gao, Fen Biao

AU - Burton, Edward A.

AU - Chow, Tiffany

AU - Kao, Aimee

AU - Leavitt, Blair R.

AU - Lamb, Bruce

AU - Grether, Megan

AU - Knopman, David S

AU - Cairns, Nigel J.

AU - Mackenzie, Ian R.

AU - Mitic, Laura

AU - Roberson, Erik D.

AU - Van Kammen, Daniel

AU - Cantillon, Marc

AU - Zahs, Kathleen

AU - Salloway, Stephen

AU - Morris, John

AU - Tong, Gary

AU - Feldman, Howard

AU - Fillit, Howard

AU - Dickinson, Susan

AU - Khachaturian, Zaven

AU - Sutherland, Margaret

AU - Farese, Robert

AU - Miller, Bruce L.

AU - Cummings, Jeffrey

PY - 2013/3

Y1 - 2013/3

N2 - Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has identified a number of promising therapeutic targets as well as animal models in which to develop drugs. The close association of some forms of FTD with neuropathological accumulation of tau protein or increased neuroinflammation due to progranulin protein deficiency suggests that a drug's success in treating FTD may predict efficacy in more common diseases such as Alzheimer's disease. A variety of regulatory incentives, clinical features of FTD such as rapid disease progression, and relatively pure molecular pathology suggest that there are advantages to developing drugs for FTD as compared with other more common neurodegenerative diseases such as Alzheimer's disease. In March 2011, the Frontotemporal Degeneration Treatment Study Group sponsored a conference entitled "FTD, the Next Therapeutic Frontier," which focused on preclinical aspects of FTD drug development. The goal of the meeting was to promote collaborations between academic researchers and biotechnology and pharmaceutical researchers to accelerate the development of new treatments for FTD. Here we report the key findings from the conference, including the rationale for FTD drug development; epidemiological, genetic, and neuropathological features of FTD; FTD animal models and how best to use them; and examples of successful drug development collaborations in other neurodegenerative diseases.

AB - Frontotemporal degeneration (FTD) is a common cause of dementia for which there are currently no approved therapies. Over the past decade, there has been an explosion of knowledge about the biology and clinical features of FTD that has identified a number of promising therapeutic targets as well as animal models in which to develop drugs. The close association of some forms of FTD with neuropathological accumulation of tau protein or increased neuroinflammation due to progranulin protein deficiency suggests that a drug's success in treating FTD may predict efficacy in more common diseases such as Alzheimer's disease. A variety of regulatory incentives, clinical features of FTD such as rapid disease progression, and relatively pure molecular pathology suggest that there are advantages to developing drugs for FTD as compared with other more common neurodegenerative diseases such as Alzheimer's disease. In March 2011, the Frontotemporal Degeneration Treatment Study Group sponsored a conference entitled "FTD, the Next Therapeutic Frontier," which focused on preclinical aspects of FTD drug development. The goal of the meeting was to promote collaborations between academic researchers and biotechnology and pharmaceutical researchers to accelerate the development of new treatments for FTD. Here we report the key findings from the conference, including the rationale for FTD drug development; epidemiological, genetic, and neuropathological features of FTD; FTD animal models and how best to use them; and examples of successful drug development collaborations in other neurodegenerative diseases.

KW - Frontotemporal degeneration

KW - Progranulin

KW - Tau

KW - TDP-43

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84875367680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875367680&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2012.03.002

DO - 10.1016/j.jalz.2012.03.002

M3 - Article

VL - 9

SP - 176

EP - 188

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 2

ER -